CA3017028C - Fibrotic treatment - Google Patents

Fibrotic treatment Download PDF

Info

Publication number
CA3017028C
CA3017028C CA3017028A CA3017028A CA3017028C CA 3017028 C CA3017028 C CA 3017028C CA 3017028 A CA3017028 A CA 3017028A CA 3017028 A CA3017028 A CA 3017028A CA 3017028 C CA3017028 C CA 3017028C
Authority
CA
Canada
Prior art keywords
inhibitor
fibrosis
irap
optionally substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3017028A
Other languages
English (en)
French (fr)
Other versions
CA3017028A1 (en
Inventor
Siew Yeen Chai
Robert Widdop
Tracey Gaspari
Huey Wen Lee
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903035A external-priority patent/AU2015903035A0/en
Application filed by Monash University filed Critical Monash University
Publication of CA3017028A1 publication Critical patent/CA3017028A1/en
Application granted granted Critical
Publication of CA3017028C publication Critical patent/CA3017028C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3017028A 2015-07-30 2016-07-29 Fibrotic treatment Active CA3017028C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903035 2015-07-30
AU2015903035A AU2015903035A0 (en) 2015-07-30 Fibrotic treatment
PCT/AU2016/050681 WO2017015720A1 (en) 2015-07-30 2016-07-29 Fibrotic treatment

Publications (2)

Publication Number Publication Date
CA3017028A1 CA3017028A1 (en) 2017-02-02
CA3017028C true CA3017028C (en) 2020-06-16

Family

ID=57883919

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3017028A Active CA3017028C (en) 2015-07-30 2016-07-29 Fibrotic treatment

Country Status (8)

Country Link
US (5) US10100311B2 (https=)
EP (1) EP3328384B1 (https=)
JP (3) JP2018527330A (https=)
AU (1) AU2016301113B2 (https=)
CA (1) CA3017028C (https=)
HK (1) HK1256423A1 (https=)
SG (1) SG11201808478RA (https=)
WO (1) WO2017015720A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016259977A1 (en) * 2015-05-08 2017-11-23 Monash University 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
CA3017028C (en) 2015-07-30 2020-06-16 Monash University Fibrotic treatment
AU2018303333B2 (en) * 2017-07-17 2023-02-09 Monash University Angiotensin receptor agonists and uses thereof
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体
WO2021050089A1 (en) * 2019-09-09 2021-03-18 Washington State University Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis
TW202143994A (zh) 2020-02-19 2021-12-01 美商希皮恩製藥公司 環孢素類似物於治療纖維化之用途
EP4440570A1 (en) * 2021-12-01 2024-10-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553688A (en) * 2004-09-09 2011-05-27 Florey Howard Inst Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase
CN101247819A (zh) * 2005-08-23 2008-08-20 惠氏公司 治疗焦虑症和鉴定抗焦虑剂的方法
WO2009065169A1 (en) * 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
KR20150028761A (ko) 2011-12-16 2015-03-16 타릭스 파마슈티컬스 엘티디. 섬유증 치료용 안지오텐신
JP2015509483A (ja) * 2012-02-06 2015-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 線維症を治療するためのｐｉ３ｋ阻害剤
JP6327923B2 (ja) 2014-04-25 2018-05-23 旭化成株式会社 ポリアセタール樹脂組成物、及びそれからなる成形体
DE102014114090A1 (de) 2014-09-29 2016-03-31 Karlsruher Institut für Technologie Verfahren zur Abtrennung von Aluminium bei der Calciumsilikatproduktion
US9519061B2 (en) * 2014-12-26 2016-12-13 Here Global B.V. Geometric fingerprinting for localization of a device
AU2016259977A1 (en) * 2015-05-08 2017-11-23 Monash University 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
CA3017028C (en) * 2015-07-30 2020-06-16 Monash University Fibrotic treatment

Also Published As

Publication number Publication date
US11078488B2 (en) 2021-08-03
HK1256423A1 (zh) 2019-09-20
JP2023030022A (ja) 2023-03-07
WO2017015720A1 (en) 2017-02-02
US20240084308A1 (en) 2024-03-14
AU2016301113A1 (en) 2018-02-22
EP3328384B1 (en) 2020-07-29
JP2018527330A (ja) 2018-09-20
EP3328384A1 (en) 2018-06-06
US20190249179A1 (en) 2019-08-15
JP2020189845A (ja) 2020-11-26
EP3328384A4 (en) 2019-03-06
US20210340547A1 (en) 2021-11-04
CA3017028A1 (en) 2017-02-02
JP7457360B2 (ja) 2024-03-28
SG11201808478RA (en) 2018-10-30
US20200362354A1 (en) 2020-11-19
US11834663B2 (en) 2023-12-05
US10100311B2 (en) 2018-10-16
AU2016301113B2 (en) 2019-10-03
US20180223287A1 (en) 2018-08-09
US10787668B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
US11834663B2 (en) Fibrotic treatment
JP7050751B2 (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
ES2892954T3 (es) Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos
ES2599002T3 (es) Inhibidores específicos para receptores del factor de crecimiento endotelial vascular
KR102347721B1 (ko) 섬유성 질환의 치료에 사용하기 위한 ppar 화합물
US20080139585A1 (en) Specific inhibitors for vascular endothelial growth factor receptors
ES2910049T3 (es) Moduladores heterocíclicos de la síntesis de lípidos
TW200948360A (en) Use of epothilone D in treating Tau-associated diseases including alzheimer's disease
CA2918340C (en) Rhynchophylline derivatives and their use as epha4 inhibitors for neuroprotection
KR20170132333A (ko) 글루타미나제 억제제에 의한 폐암의 치료
JP2024161441A (ja) 呼吸器疾患の処理のための新規な化合物
CN110573514A (zh) 含有紫花前胡素衍生物作为有效成分的老化相关疾病的预防或治疗用药物组合物
ES3002189T3 (en) Para-hydroquinone derivatives as vegf, tnf and/or il inhibitors for the treatment of neuroinflammatory diseases
JP2025528014A (ja) ナフチルアミン構造を有する低分子化合物の使用
CN111494380A (zh) Db-1在制备防治nlrp3炎症小体相关疾病的药物中的应用及其药物组合物
US20230159438A1 (en) Arylamides and methods of use thereof
ES2553862T3 (es) Formulaciones que comprenden compuestos de triptán
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
CN116829165A (zh) 用于预防、治疗或减轻病毒感染性疾病或呼吸道疾病的包含副干酪乳杆菌来源的囊泡的组合物
JP2025505820A (ja) サルササポゲニン構造に基づく誘導体およびその医薬組成物の使用
CN102171215B (zh) 7H-咪唑并[1,2-a]吡喃并[2,3-c]吡啶类衍生物及其应用
HK40121103A (zh) 新型分子胶的用途
KR20100004681A (ko) ｐ21의 발현을 증가시키는 활성을 갖는 화합물5,4'-디메톡시플라본의 항암제로서의 용도
JP2014141472A (ja) １，３，５−トリアジン誘導体を有する線維化予防又は治療剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190111

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240719

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250723

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250723